Actively Recruiting
Prognostic Role of the Uremic Toxin Indoxyl Sulfate on Vascular and Cardiac Functions During Acute Kidney Injury
Led by Centre Hospitalier Universitaire, Amiens · Updated on 2025-05-28
105
Participants Needed
1
Research Sites
39 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying acute kidney injury (AKI), a common condition in hospital and intensive care settings, which increases the risk of developing chronic kidney disease and cardiovascular problems. The study aims to understand if high levels of uremic toxins, particularly Indoxyl sulfate (IS), during AKI are linked to early changes in blood vessel stiffness and heart function. This investigation focuses on measuring arterial stiffness using pulse wave velocity (PWV) three months after an AKI episode. Participants will undergo blood sample collections to measure various substances including IS, Para-cresyl Sulfate (PCS), Fibroblast Growth Factor 23 (FGF-23), and markers related to vascular and cardiac health. The study is non-randomized and uses a double masking approach to assess correlations between these substances and vascular and cardiac outcomes. Measurements and assessments are done in both conventional hospital departments and nephrology intensive care units. During the study, participants will have their pulse wave velocity measured at baseline and again three months after the AKI episode to observe changes. Blood samples will be analyzed for several biomarkers including serum creatinine, IS, PCS, FGF-23, and others linked to heart and vascular function. The main outcome is the change in PWV from baseline after three months. The study also evaluates other cardiovascular and arterial health markers, with participation lasting at least three months.
CONDITIONS
Brief Title
Prognostic Role of the Uremic Toxin Indoxyl Sulfate on Vascular and Cardiac Functions During Acute Kidney Injury
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 18 years old
- Hospitalized in conventional hospital departments or nephrology intensive care units
- Moderate to severe acute kidney injury (KDIGO stage 2 or 3) without dialysis
- AKI caused by functional or organic reasons
You will not qualify if you...
- Severe chronic kidney disease (GFR <45 ml/min/1.73 m2) or kidney transplant
- AKI caused by septic or obstructive reasons
- AKI from toxic causes affecting the heart
- Presence of sepsis or blood inflammation
- Severe chronic heart dysfunction
- Arrhythmia or complete heart block
- Peripheral artery occlusive disease
- Pregnancy
- Receiving palliative care
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 months
Participants undergo blood sample collection to measure various biomarkers related to kidney injury and vascular and cardiac functions.
1 baseline visit and 1 follow-up visit
Trial Site Locations
Total: 1 location
1
Amiens hospital
Amiens, France, 80000
Actively Recruiting
Research Team
P
Pauline Caillard, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here